# Efficacy, Pharmacokinetics, Tolerability, Safety of SB012 Intrarectally Applied in Active Ulcerative Colitis Patients

> **NCT02129439** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sterna Biologicals GmbH & Co. KG** · enrollment: 20 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** SB012
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02129439
- **Lead sponsor:** Sterna Biologicals GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2017-06-22
- **Final completion:** 2017-06-22
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02129439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02129439, "Efficacy, Pharmacokinetics, Tolerability, Safety of SB012 Intrarectally Applied in Active Ulcerative Colitis Patients". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT02129439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*